The company said that recent study results show its Aventa Lymphoma test can provide actionable information that would typically be missed by FISH testing.

Revenues from the Life Sciences business unit, which is on track to be sold to Waters in Q1 2026, rose 2 percent to $1.37 billion.

Third quarter revenues dipped 4 percent as reported but rose 5 percent excluding results from COVID-19 testing and the donor screening business the firm is exiting.

For the fourth quarter, the point-of-care diagnostics company anticipates revenues of between $25 million and $28 million.

Parent firm Siemens is considering reducing its ownership stake in Siemens Healthineers, which could mean the termination of existing financing agreements.

The firm's data and services revenues grew 26 percent to $81.3 million, while genomics revenues more than doubled to $252.9 million.

The firm said that growth in its immunodiagnostics business was offset by contraction in its molecular diagnostics, licensed technologies, and COVID-19 businesses.

These drugs, which are among the most common types of blood thinners, can interfere with traditional coagulation tests, producing unreliable results.